TITLE

Adipose Dipeptidyl Peptidase-4 and Obesity

AUTHOR(S)
SELL, HENRIKE; BLUHER, MATTHIAS; KLÖTING, NORA; SCHLICH, RAPHAELA; WILLEMS, MIRIAM; RUPPE, FLORIAN; KNOEFEL, WOLFRAM TRUDO; DIETRICH, ARNE; FIELDING, BARBARA A.; ARNER, PETER; FRAYN, KEITH N.; ECKEL, JURGEN
PUB. DATE
December 2013
SOURCE
Diabetes Care;Dec2013, Vol. 36 Issue 12, p4083
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE--To study expression of the recently identified adipokine dipeptidyl peptidase-4 (DPP4) in subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) of patients with various BMIs and insulin sensitivities, as well as to assess circulating DPP4 in relation to obesity and insulin sensitivity. RESEARCH DESIGN AND METHODS--DPP4 expression was measured in SAT and VAT from 196 subjects with a wide range of BMIs and insulin sensitivities. DPP4 release was measured ex vivo in paired biopsies from SAT and VAT as well as in vivo from SAT of lean and obese patients. Circulating DPP4 was measured in insulin-sensitive and insulin-resistant BMI-matched obese patients. RESULTS--DPP4 expression was positively correlated with BMI in both SAT and VAT, with VAT consistently displaying higher expression than SAT. Ex vivo release of DPP4 from adipose tissue explants was higher in VAT than in SAT in both lean and obese patients, with obese patients displaying higher DPP4 release than lean controls. Net release of DPP4 from adipose tissue was also demonstrated in vivo with greater release in obese subjects than in lean subjects and in women than in men. Insulin-sensitive obese patients had significantly lower circulating DPP4 than did obesity-matched insulin-resistant patients. In this experiment, DPP4 positively correlated with the amount of VAT, adipocyte size, and adipose tissue inflammation. CONCLUSIONS--DPP4, a novel adipokine, has a higher release from VAT that is particularly pronounced in obese and insulin-resistant patients. Our data suggest that DPP4 may be a marker for visceral obesity, insulin resistance, and the metabolic syndrome.
ACCESSION #
92533606

 

Related Articles

  • Effects of Naltrexone Sustained-Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes. HOLLANDER, PRISCILLA; GUPTA, ALOK K.; PLODKOWSKI, RAYMOND; GREENWAY, FRANK; BAYS, HAROLD; BURNS, COLLEEN; KLASSEN, PRESTON; FUJIOKA, KEN // Diabetes Care;Dec2013, Vol. 36 Issue 12, p4022 

    OBJECTIVE--To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/ 360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs. RESEARCH DESIGN AND METHODS--This was a 56-week, double-blind,...

  • In This Issue of Diabetes Care. Resnick, Helaine E. // Diabetes Care;Oct2014, Vol. 37 Issue 10, p2663 

    The article discusses various reports published within this issue including one on a study on the effect of albiglutide on diabetic patients, one on the importance of HbA testing to patients with diabetes and one on the effect of fetal hyperglycemia exposure on patients with gestational diabetes...

  • Treatment Effects on Measures of Body Composition in the TODAY Clinical Trial. El ghormli, Laure // Diabetes Care;Jun2013, Vol. 36 Issue 6, p1742 

    OBJECTIVE--The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial showed superiority of metformin plus rosiglitazone (M+R) over metformin alone (M), with metformin plus lifestyle (M+L) intermediate in maintaining glycemic control. We report here treatment effects on...

  • Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin. FERRANNINI, ELE; BERK, ANDREAS; HANTEL, STEFAN; PINNETTI, SABINE; HACH, THOMAS; WOERLE, HANS J.; BROEDL, ULI C. // Diabetes Care;Dec2013, Vol. 36 Issue 12, p4015 

    OBJECTIVE--To investigate the long-term safety and efficacy of empagliflozin, a sodium glucose cotransporter 2 inhibitor; sitagliptin; and metformin in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS--In this randomized, open-label, 78-week extension study of two 12-week, blinded,...

  • A functional polymorphism in the promoter of UCP2 enhances obesity risk but reduces type 2 diabetes risk in obese middle-aged humans. Krempler, Franz; Esterbauer, Harald; Weitgasser, Raimund; Ebenbichler, Christoph; Patsch, Josef R.; Miller, Karl; Xie, Mingqiang; Linnemayr, Veronika; Oberkofler, Hannes; Patsch, Wolfgang // Diabetes;Nov2002, Vol. 51 Issue 11, p3331 

    Obesity is frequently associated with type 2 diabetes. We previously observed an association of a functional G/A polymorphism in the uncoupling protein 2 (UCP2) promoter with obesity. The wild-type G allele was associated with reduced adipose tissue mRNA expression in vivo, reduced...

  • Stimulatory Effect of Insulin on Glucose Uptake by Muscle Involves the Central Nervous System in Insulin-Sensitive Mice. Coomans, Claudia P.; Biermasz, Nienke R.; Geerling, Janine J.; Guigas, Bruno; Rensen, Patrick C. N.; Havekes, Louis M.; Romijn, Johannes A. // Diabetes;Dec2011, Vol. 60 Issue 12, p3132 

    OBJECTIVE--Insulin inhibits endogenous glucose production (EGP) and stimulates glucose uptake in peripheral tissues. Hypothalamic insulin signaling is required for the inhibitory effects of insulin on EGP. We examined the contribution of central insulin signaling on circulating...

  • Tissue Distribution of S-(2-Succino)cysteine (2SC), a Biomarker of Mitochondrial Stress in Obesity and Diabetes. Thomas, Sonia A.; Storey, Kenneth B.; Baynes, John W.; Frizzell, Norma // Obesity (19307381);Feb2012, Vol. 20 Issue 2, p263 

    S-(2-succino)cysteine (2SC) is a chemical modification of proteins produced by reaction of fumarate with thiol groups in protein, a process known as succination. We propose to use the name S-(2-succino)cysteine (instead of S-(2-succinyl)cysteine) from this point on. This is to distinguish...

  • Comparison of Adiponectin Values in Obese and Nonobese Diabetics and Relationship with Metabolic Parameters. ERDENEN, Füsun; KOCAÖZ, Yasin; CİVELEK, Sabiha; AKBAŞ, Feray; ALTUNOĞLU, Esma; UZUN, Hafize // Istanbul Medical Journal;2012, Vol. 13 Issue 3, p105 

    Adipose tissue stores energy and acts as an active endocrine organ that secretes adiponectin. It is noted that adiponectin level is decreased in obesity and metabolic syndrome. The aim of this study was to measure the adiponectin levels of obese and non-obese patients previously diagnosed with...

  • Tumor Progression Locus 2 (TPL2) Regulates Obesity-Associated Inflammation and Insulin Resistance. Perfield II, James W.; Yunkyoung Lee; Shulman, Gerald I.; Samuel, Varman T.; Jurczak, Michael J.; Chang, Eugene; Chen Xie; Tsichlis, Phillip N.; Obin, Martin S.; Greenberg, Andrew S. // Diabetes;Apr2011, Vol. 60 Issue 4, p1168 

    OBJECTIVE--Obesity-associated low-grade systemic inflammation resulting from increased adipose mass is strongly related to the development of insulin resistance and type 2 diabetes as well as other metabolic complications. Recent studies have demonstrated that the obese metabolic state can be...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics